NCT07262814

Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini

Efficacy, Safety and Acceptability of Ascending Doses of Arpraziquantel for Opisthorchis Viverrini Infections in Children Aged 6-7 Years: A Single-blind Randomized Dose-ranging Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (estimated)
• Sponsor: Jennifer Keiser · Academic / Other
• Sex: All
• Age: 6 Years – 7 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess the efficacy, safety and acceptability of ascending doses of arpraziquantel in children infected with Opisthorchis viverrini. The primary objective is to determine the dose-response relationship in terms of cure rate. This study will involve children aged 6-7 years, since O. viverrini infections often occur in pre-school and school-aged children, and this group is largely left untreated in current public health programs.

Conditions

• Opisthorchis Viverrini

Interventions

Type	Name	Description
DRUG	Apraziquantel	Tablets (dispersible) containing 150 mg arpraziquantel

Timeline

• Start date: 2026-04-15
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2025-12-04
• Last updated: 2026-03-20

Locations

1 site across 1 country: Laos